drugset / Trial / NCT03021785
A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open-label study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of multiple intravitreal injection TK001 in patients with AMD. It consists of core study (12 weeks) and extension study (40 weeks).
Timeline
- Start
- 2017-10-18
- Primary completion
- 2018-11
- Completion
- 2018-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TK001 | Monoclonal antibody | 0.5 mg | Intravitreal |
| Subject | TK001 | Monoclonal antibody | 1 mg | Intravitreal |
| Subject | TK001 | Monoclonal antibody | 1.5 mg | Intravitreal |